BD Elevates U.S. Medical Device Production for Healthcare

BD Ramps Up U.S. Manufacturing of Essential Medical Devices

BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent medical technology company, has announced substantial investments aimed at boosting its U.S. manufacturing capabilities. This initiative focuses on increasing the production capacity for critical medical devices such as syringes, needles, and IV catheters, addressing the persistent needs of the healthcare system in the country.

Significant Investments in Manufacturing Capacity

To enhance its manufacturing footprint in the U.S., BD is committing over $10 million as part of its 2024 investment plan. New production lines dedicated to needles and syringes have been installed in BD’s plants, resulting in improved capabilities to meet healthcare demands. These production enhancements are set to significantly increase the company’s ability to manufacture safety-engineered injection devices by over 40 percent and conventional syringes by more than 50 percent. This translates to adding hundreds of millions of units each year, which are vital for hospitals, vaccinations, medication preparation, and drug delivery.

Employment Growth at BD Plants

In conjunction with this expansion, BD has bolstered its workforce by hiring over 215 full-time employees across its plants. These new team members will help support and manage the increased production, ensuring that BD can continue to meet the urgent demands of the healthcare sector effectively.

Future Investments to Sustain Growth

Looking ahead, BD has outlined plans for additional investments exceeding $30 million in 2025 to further expand its manufacturing capacity for IV lines at its plant. This expansion is key to supporting the ongoing development of catheter solutions. Following a successful investment of $2 million in 2024 for IV line improvements, the company has already seen a rise in output of IV catheters by more than 40 million units annually.

A Commitment to Resilient Domestic Manufacturing

"Domestic manufacturing is critical for ensuring a dependable supply of essential health care devices," shared Eric Borin, president of Medication Delivery Solutions at BD. He emphasized that expanding production capacity not only addresses the immediate needs of patients and providers but also strengthens the overall healthcare infrastructure in the nation.

Legacy of Manufacturing Excellence

BD’s substantial investments are a testament to its long-standing commitment to the resilience of the U.S. healthcare supply chain. With over 120 years of manufacturing excellence, BD operates multiple key facilities across the country, collectively reflecting 200 years of manufacturing experience. Facilities in Nebraska, Connecticut, and Utah represent the only remaining large-scale syringe manufacturing locations in the U.S.

BD’s Manufacturing Presence Across the United States

The BD facility in Columbus, Nebraska, established in 1949, spans over one million square feet and employs more than 2,000 workers. Similarly, the Canaan, Connecticut, site opened in 1961, covering 385,000 square feet and employing over 540 people. Additionally, the Sandy, Utah, facility, opened in 1956, is recognized as the world’s largest producer of IV catheter lines, employing about 1,200 associates in its 650,000 square feet of operations.

Impact on the Healthcare Supply Chain

With a robust presence of over 30 manufacturing and distribution facilities across the U.S., BD plays a pivotal role in the medical product supply chain. Employing more than 10,000 people, these facilities are vital to maintaining the integrity and efficiency of healthcare delivery across 17 states and Puerto Rico.

About BD

BD stands as one of the largest global medical technology companies, dedicated to improving medical discovery, diagnostics, and care delivery. The company empowers healthcare heroes through innovative technologies, services, and solutions aimed at enhancing clinical therapy for patients and efficiency for healthcare providers. With a workforce of over 70,000, BD collaborates with organizations worldwide to address pressing global health challenges. For more details, visit bd.com or connect with BD on social media platforms.

Frequently Asked Questions

What new investments is BD making in U.S. manufacturing?

BD is investing over $10 million in 2024 to expand the capacity for producing syringes and needles at its U.S. facilities.

How will these investments affect production levels?

The investments are expected to increase the production capacity for safety-engineered injection devices by over 40% and conventional syringes by more than 50%.

What specific products are being focused on with this expansion?

BD is primarily focusing on syringes, needles, and IV catheters as part of its enhanced manufacturing strategy.

How many employees has BD hired for this expansion?

BD has hired over 215 new full-time employees to support the increased production at its plants.

What is BD's legacy in the U.S. manufacturing sector?

BD has over 120 years of manufacturing excellence, making significant contributions to the healthcare supply chain with multiple facilities dedicated to the production of critical medical devices.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.